Nektar Therapeutics (NKTR) Tops Q1 EPS by 97c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $74.90 +2.39%
Revenue Growth %: -7.1%
Financial Fact:
General and administrative: 10.25M
Today's EPS Names:
EPAC, SAR, KRUS, More
Revenue Growth %: -7.1%
Financial Fact:
General and administrative: 10.25M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of $0.73, $0.97 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $20.11 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
- ExxonMobil outlines key factors for Q2 2026 earnings outlook
- UBS Reiterates Buy Rating on Smurfit Westrock (SW)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
